<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03824691</url>
  </required_header>
  <id_info>
    <org_study_id>INT 180/18</org_study_id>
    <nct_id>NCT03824691</nct_id>
  </id_info>
  <brief_title>hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study&quot;</brief_title>
  <acronym>ARCADIA</acronym>
  <official_title>Cabozantinib Plus Durvalumab in Patients With Advanced and Chemotherapy-treated Bladder Carcinoma, of Urothelial and Non-urothelial Histology: an Open-label, Single-centre, Phase 2, Single-arm Proof-of-concept Trial: ARCADIA Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cabozantinib plus Durvalumab in patients with advanced and chemotherapy-treated bladder
      carcinoma, of urothelial and non-urothelial histology: an open-label, single-centre, phase 2,
      single-arm proof-of-concept trial: ARCADIA study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      an open-label, single-centre, phase 2,
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 25, 2019</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint of the study will be overall survival (OS).</measure>
    <time_frame>48 months</time_frame>
    <description>to evaluate whether the combination of durvalumab and cabozantinib will be active and will result in an increased efficacy compared to the available results with the use of both single-agents</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability).</measure>
    <time_frame>48 months</time_frame>
    <description>incidence, nature and severity of all-cause and treatment-related adverse events (AE), graded with the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival (PFS)</measure>
    <time_frame>48 months</time_frame>
    <description>RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>responses to treatment</measure>
    <time_frame>48 months</time_frame>
    <description>Assessment of RR (investigator-assessed) according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria. RR (%) = complete (CR) + partial responses (PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response duration</measure>
    <time_frame>48 months</time_frame>
    <description>PET-responses according to the EORTC criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of activity and efficacy of either agents and their combination.</measure>
    <time_frame>48 months</time_frame>
    <description>determination of a patient's PD-L1 status. Biomarkers Blood Collection will be performend at baseline, every 2 cycles and progression disease</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>Bladder Carcinoma</condition>
  <arm_group>
    <arm_group_label>Cabozantinib + Durvalumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 1500 mg durvalumab (MEDI4736) IV infusion every 28 days + Cabozantinib 40 mg orally once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabozantinib</intervention_name>
    <description>cabozantinib 40 mg orally once daily</description>
    <arm_group_label>Cabozantinib + Durvalumab</arm_group_label>
    <other_name>CABOMETYX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>1500 mg durvalumab (MEDI4736) IV infusion every 28 days</description>
    <arm_group_label>Cabozantinib + Durvalumab</arm_group_label>
    <other_name>Imfinzi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent.

          -  Age ≥18 years.

          -  Body weight &gt;30kg

          -  Histologically-confirmed diagnosis of UC or variant histologies (e.g. squamous cell
             carcinoma, adenocarcinoma, micropapillary tumors, BUT excluding pure small cell
             carcinoma) of the bladder or the urothelium.

          -  Either bladder, urethral, or upper tract primary tumor will be allowed.

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.

          -  Life expectancy of at ≥ 12 weeks.

          -  Availability of tumor tissue for PD-L1 IHC assay.

          -  Measurable and non-measurable disease will be included (e.g. patients with bone
             metastases only will be allowed for inclusion).

          -  Failure of 1 or 2 cisplatin-based conventional chemotherapy regimens for metastatic
             disease (2nd-to-3rd line only).

          -  Neoadjuvant/adjuvant regimens will be counted provided that a relapse occurred with 6
             months of the last cycle of chemotherapy.

          -  Adequate function of the organs:

               1. Absolute neutrophil count (ANC) ≥ 1500/mm3

               2. Platelets ≥ 100,000/mm3

               3. Hemoglobin ≥ 9 g/dL (≥ 90 g/L).

               4. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) &lt; 3.0 × upper
                  limit of normal.

               5. Total bilirubin ≤ 1.5 × the upper limit of normal. For subjects with Gilbert's
                  disease ≤ 3 mg/dL

             g. Serum creatinine ≤ 2.0 × upper limit of normal or calculated creatinine clearance ≥
             30 mL/min using the Cockroft-Gault equation h. Lipase &lt; 2.0 times the upper limit of
             normal (ULN)

          -  Recovery to baseline or ≤ Grade 1 Common Terminology Criteria for Adverse Events
             (CTCAE) v5.0 from toxicities related to any prior treatments, unless AE(s) are
             clinically nonsignificant and/or stable on supportive therapy

          -  Ability to swallow tablets

          -  Contraception for sexually active fertile patients and their partners. Of note, a
             barrier method is recommended in addition to the use of steroid hormonal
             contraceptives, because the effects of cabozantinib on the pharmacokinetics of the
             latter are unknown.

          -  Evidence of post menopausal status or serum pregnancy test for female pre-menopausal
             subject

        Exclusion Criteria:

          -  Patients taking regular oral steroids, above the allowed limit of 10mg/day
             methylprednisolone or analogues, for any reason. Patients must not have had steroids
             for 28 days prior to study entry.

          -  Malignancies other than bladder carcinoma within 5 years prior to Cycle 1, Day 1, with
             the exception of those with a negligible risk of metastasis or death and treated with
             expected curative outcome (such as adequately treated carcinoma in situ of the cervix,
             basal or squamous cell skin cancer, or ductal carcinoma in situ treated surgically
             with curative intent) or localized prostate cancer treated with curative intent and
             absence of prostate-specific antigen (PSA) relapse or incidental prostate cancer
             (Gleason score ≤ 3 + 4 and PSA &lt; 10 ng/mL undergoing active surveillance and treatment
             naive).

          -  Evidence of significant uncontrolled concomitant disease that could affect compliance
             with the protocol or interpretation of results.

          -  Active or untreated CNS metastases as determined by computed tomography (CT) or
             magnetic resonance imaging evaluation during screening and prior radiographic
             assessments.

          -  Patients with treated asymptomatic CNS metastases are eligible, provided they meet all
             of the following criteria:

               1. Evaluable or measurable disease outside the CNS

               2. No metastases to midbrain, pons, medulla, or within 10 mm of the optic apparatus
                  (optic nerves and chiasm)

               3. No history of intracranial or spinal cord hemorrhage

               4. No ongoing requirement for corticosteroid as therapy for CNS disease;
                  anti-convulsants at a stable dose are allowed

               5. No evidence of significant vasogenic edema

               6. No stereotactic radiation, whole-brain radiation or neurosurgical resection
                  within 4 weeks prior to Cycle 1, Day 1

               7. Radiographic demonstration of interim stability (i.e., no progression) between
                  the completion of CNS-directed therapy and the screening radiographic study

               8. Screening CNS radiographic study ≥ 4 weeks since completion of radiotherapy or
                  surgical resection and ≥ 2 weeks since discontinuation of corticosteroids

          -  Pregnant female patients. All female patients of childbearing potential with a
             positive pregnancy test within 2 weeks prior to the first dose of study treatment will
             be excluded from the study.

          -  Clinically significant cardiovascular disease, for example, myocardial infarction
             (within 3months prior to enrolment), unstable angina, New York Heart Association
             (NYHA) grade II or greater congestive heart failure or serious cardiac arrhythmia
             requiring medication (beta-blockers and digoxin are allowed)

          -  Uncontrolled hypertension, stroke or other ischemic or thromboembolic event (DVT, PE)
             within 6 months before first dose of cabozantinib.

          -  Severe infections within 4 weeks prior to enrolment in the study including but not
             limited to hospitalization for complications of infection, bacteraemia, or severe
             pneumonia.

          -  Major surgical procedure within 4 weeks prior to enrolmentor anticipation of need for
             a major surgical procedure during the course of the study other than for diagnosis.
             Complete wound healing from major surgery must have occurred 1 month before inclusion
             and from minor surgery (eg, simple excision, tooth extraction) at least 10 days before
             inclusion. Subjects with clinically relevant ongoing complications from prior surgery
             are not eligible.

          -  Received therapeutic oral or intravenous (IV) antibiotics within 2 weeks prior to
             enrolment (patients receiving prophylactic antibiotics, e.g., for prevention of a
             urinary tract infection or chronic obstructive pulmonary disease, are eligible).

          -  Concomitant anticoagulation with oral anticoagulants or platelet inhibitors.

          -  History of autoimmune disease including, but not limited to, myasthenia gravis,
             myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis,
             inflammatory bowel disease, vascular thrombosis associated with antiphospholipid
             syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome,
             multiple sclerosis, vasculitis, or glomerulonephritis.

          -  Patients with a history of autoimmune-related hypothyroidism, unless on a stable dose
             of thyroid-replacement hormone.

          -  Patients with uncontrolled Type 1 diabetes mellitus

          -  Uncontrolled hypercalcemia (&gt; 1.5 mmol/L ionized calcium or Ca &gt; 12 mg/dL or corrected
             serum calcium &gt; ULN) or symptomatic hypercalcemia requiring continued use of
             bisphosphonate therapy or denosumab. Patients who are receiving bisphosphonate therapy
             or denosumab specifically to prevent skeletal events and who do not have a history of
             clinically significant hypercalcemia are eligible. Patients who are receiving
             denosumab prior to enrollment must be willing and eligible to receive a bisphosphonate
             instead while on study.

          -  radiation therapy for bone within 2 weeks or other radiation therapy within 4 weeks
             before first dose of study treatment. patients with clinically relevant ongoing
             complications from prior radiation therapy

          -  serious non healing wound/ulcer/bone fracture, moderate to severe hepatic impairment
             (Child Pugh B or C)

          -  History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced
             pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic
             organizing pneumonia), or evidence of active pneumonitis on screening chest CT scan
             (History of radiation pneumonitis in the radiation field (fibrosis) is permitted).

          -  Patients with tumors invading major pulmonary vessels and/or with cavitating pulmonary
             lesions.

          -  Positive test for HIV.

          -  Patients with active hepatitis infection (defined as having a positive hepatitis B
             surface antigen [HBsAg] test at screening) or hepatitis C. Patients with past
             hepatitis B virus (HBV) infection or resolved HBV infection (defined as having a
             negative HBs Ag test and a positive antibody to hepatitis B core antigen [anti-HBc]
             antibody test) are eligible. Patients positive for hepatitis C virus (HCV) antibody
             are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.

          -  Patients with active tuberculosis.

          -  Gastrointestinal disorders likely to interfere with absorption of the study drug (e.g.
             partial bowel obstruction or malabsorption).

          -  Subjects with gastrointestinal disorders associated with a high risk of perforation or
             fistula formation

          -  Subjects with active peptic ulcer or with a history of clinically significant GI
             bleeding within 12 weeks before the first dose of study treatment

          -  Prior treatment with CD137 agonists, anti-PD-1, or anti-PD-L1 therapeutic antibody or
             pathway-targeting agents.

          -  Administration of a live, attenuated vaccine within 4 weeks prior to enrolment or
             anticipation that such a live, attenuated vaccine will be required during the study.

          -  Treatment with any other investigational agent or participation in another clinical
             trial with therapeutic intent within 28 days prior to enrolment.

          -  Treatment with systemic immunostimulatory agents (including but not limited to
             interferons or interleukin [IL]−2) within 4 weeks or five half-lives of the drug,
             whichever is shorter, prior to enrolment.

          -  Rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or
             glucose-galactose malabsorption
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andrea Necchi, MD</last_name>
    <phone>+390223902402</phone>
    <email>andrea.necchi@istitutotumori.mi.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rosanna Montone, Dr.ssa</last_name>
    <phone>+390223903817</phone>
    <email>rosanna.montone@istitutotumori.mi.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale Tumori</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Necchi, MD</last_name>
      <phone>+390223902402</phone>
      <email>andrea.necchi@istitutotumori.mi.it</email>
    </contact>
    <contact_backup>
      <last_name>Rosanna Montone, Dr.ssa</last_name>
      <phone>+390223903817</phone>
      <email>rosanna.montone@istitutotumori.mi.it</email>
    </contact_backup>
    <investigator>
      <last_name>Andrea Necchi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström PU, Choi W, Guo CC, Lotan Y, Kassouf W. Bladder cancer. Lancet. 2016 Dec 3;388(10061):2796-2810. doi: 10.1016/S0140-6736(16)30512-8. Epub 2016 Jun 23. Review. Erratum in: Lancet. 2016 Dec 3;388(10061):2742.</citation>
    <PMID>27345655</PMID>
  </results_reference>
  <results_reference>
    <citation>Necchi A, Sonpavde G, Lo Vullo S, Giardiello D, Bamias A, Crabb SJ, Harshman LC, Bellmunt J, De Giorgi U, Sternberg CN, Cerbone L, Ladoire S, Wong YN, Yu EY, Chowdhury S, Niegisch G, Srinivas S, Vaishampayan UN, Pal SK, Agarwal N, Alva A, Baniel J, Golshayan AR, Morales-Barrera R, Bowles DW, Milowsky MI, Theodore C, Berthold DR, Daugaard G, Sridhar SS, Powles T, Rosenberg JE, Galsky MD, Mariani L; RISC Investigators. Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). Eur Urol. 2017 Feb;71(2):281-289. doi: 10.1016/j.eururo.2016.09.042. Epub 2016 Oct 8.</citation>
    <PMID>27726966</PMID>
  </results_reference>
  <results_reference>
    <citation>Raggi D, Miceli R, Sonpavde G, Giannatempo P, Mariani L, Galsky MD, Bellmunt J, Necchi A. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. Ann Oncol. 2016 Jan;27(1):49-61. doi: 10.1093/annonc/mdv509. Epub 2015 Oct 20. Review.</citation>
    <PMID>26487582</PMID>
  </results_reference>
  <results_reference>
    <citation>Necchi A, Pond GR, Raggi D, Giannatempo P, Vogelzang NJ, Grivas P, Galsky MD, Bellmunt J, Sonpavde G. Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis. Clin Genitourin Cancer. 2017 Feb;15(1):23-30.e2. doi: 10.1016/j.clgc.2016.05.003. Epub 2016 May 27. Review.</citation>
    <PMID>27324051</PMID>
  </results_reference>
  <results_reference>
    <citation>Dash A, Galsky MD, Vickers AJ, Serio AM, Koppie TM, Dalbagni G, Bochner BH. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer. 2006 Aug 1;107(3):506-13.</citation>
    <PMID>16773629</PMID>
  </results_reference>
  <results_reference>
    <citation>Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg CN, Bajorin DF, Bellmunt J. Treatment of patients with metastatic urothelial cancer &quot;unfit&quot; for Cisplatin-based chemotherapy. J Clin Oncol. 2011 Jun 10;29(17):2432-8. doi: 10.1200/JCO.2011.34.8433. Epub 2011 May 9. Review.</citation>
    <PMID>21555688</PMID>
  </results_reference>
  <results_reference>
    <citation>Reardon ZD, Patel SG, Zaid HB, Stimson CJ, Resnick MJ, Keegan KA, Barocas DA, Chang SS, Cookson MS. Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides. Eur Urol. 2015 Jan;67(1):165-170. doi: 10.1016/j.eururo.2014.01.009. Epub 2014 Jan 23.</citation>
    <PMID>24472710</PMID>
  </results_reference>
  <results_reference>
    <citation>Gentzler R, Hall R, Kunk PR, Gaughan E, Dillon P, Slingluff CL Jr, Rahma OE. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors. Immunotherapy. 2016 May;8(5):583-600. doi: 10.2217/imt-2015-0029. Review.</citation>
    <PMID>27140411</PMID>
  </results_reference>
  <results_reference>
    <citation>Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, Shen X, Boyd Z, Hegde PS, Chen DS, Vogelzang NJ. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014 Nov 27;515(7528):558-62. doi: 10.1038/nature13904.</citation>
    <PMID>25428503</PMID>
  </results_reference>
  <results_reference>
    <citation>Herr HW, Morales A. History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J Urol. 2008 Jan;179(1):53-6. Epub 2007 Nov 13.</citation>
    <PMID>17997439</PMID>
  </results_reference>
  <results_reference>
    <citation>Rink M, Shariat SF, Soave A. Liquid biopsies in bladder cancer-did we find the Holy Grail for biomarker analyses? Transl Androl Urol. 2016 Dec;5(6):980-983. doi: 10.21037/tau.2016.09.03.</citation>
    <PMID>28078238</PMID>
  </results_reference>
  <results_reference>
    <citation>Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014 Mar 20;507(7492):315-22. doi: 10.1038/nature12965. Epub 2014 Jan 29.</citation>
    <PMID>24476821</PMID>
  </results_reference>
  <results_reference>
    <citation>Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, Kiezun A, Hammerman PS, McKenna A, Drier Y, Zou L, Ramos AH, Pugh TJ, Stransky N, Helman E, Kim J, Sougnez C, Ambrogio L, Nickerson E, Shefler E, Cortés ML, Auclair D, Saksena G, Voet D, Noble M, DiCara D, Lin P, Lichtenstein L, Heiman DI, Fennell T, Imielinski M, Hernandez B, Hodis E, Baca S, Dulak AM, Lohr J, Landau DA, Wu CJ, Melendez-Zajgla J, Hidalgo-Miranda A, Koren A, McCarroll SA, Mora J, Crompton B, Onofrio R, Parkin M, Winckler W, Ardlie K, Gabriel SB, Roberts CWM, Biegel JA, Stegmaier K, Bass AJ, Garraway LA, Meyerson M, Golub TR, Gordenin DA, Sunyaev S, Lander ES, Getz G. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013 Jul 11;499(7457):214-218. doi: 10.1038/nature12213. Epub 2013 Jun 16.</citation>
    <PMID>23770567</PMID>
  </results_reference>
  <results_reference>
    <citation>Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, Curiel TJ, Colon-Otero G, Hamid O, Sanborn RE, O'Donnell PH, Drakaki A, Tan W, Kurland JF, Rebelatto MC, Jin X, Blake-Haskins JA, Gupta A, Segal NH. Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. J Clin Oncol. 2016 Sep 10;34(26):3119-25. doi: 10.1200/JCO.2016.67.9761. Epub 2016 Jun 6.</citation>
    <PMID>27269937</PMID>
  </results_reference>
  <results_reference>
    <citation>Powles T, O'Donnell PH, Massard C, Arkenau HT, Friedlander TW, Hoimes CJ, Lee JL, Ong M, Sridhar SS, Vogelzang NJ, Fishman MN, Zhang J, Srinivas S, Parikh J, Antal J, Jin X, Gupta AK, Ben Y, Hahn NM. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study. JAMA Oncol. 2017 Sep 14;3(9):e172411. doi: 10.1001/jamaoncol.2017.2411. Epub 2017 Sep 14.</citation>
    <PMID>28817753</PMID>
  </results_reference>
  <results_reference>
    <citation>Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.</citation>
    <PMID>19097774</PMID>
  </results_reference>
  <results_reference>
    <citation>Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, de Vries EGE; RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017 Mar;18(3):e143-e152. doi: 10.1016/S1470-2045(17)30074-8. Epub 2017 Mar 2. Review. Erratum in: Lancet Oncol. 2019 May;20(5):e242.</citation>
    <PMID>28271869</PMID>
  </results_reference>
  <results_reference>
    <citation>Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, Pruim J, Price P. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999 Dec;35(13):1773-82.</citation>
    <PMID>10673991</PMID>
  </results_reference>
  <results_reference>
    <citation>Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, Ross DS, Hechtman JF, DeLair DF, Yao J, Mandelker DL, Cheng DT, Chandramohan R, Mohanty AS, Ptashkin RN, Jayakumaran G, Prasad M, Syed MH, Rema AB, Liu ZY, Nafa K, Borsu L, Sadowska J, Casanova J, Bacares R, Kiecka IJ, Razumova A, Son JB, Stewart L, Baldi T, Mullaney KA, Al-Ahmadie H, Vakiani E, Abeshouse AA, Penson AV, Jonsson P, Camacho N, Chang MT, Won HH, Gross BE, Kundra R, Heins ZJ, Chen HW, Phillips S, Zhang H, Wang J, Ochoa A, Wills J, Eubank M, Thomas SB, Gardos SM, Reales DN, Galle J, Durany R, Cambria R, Abida W, Cercek A, Feldman DR, Gounder MM, Hakimi AA, Harding JJ, Iyer G, Janjigian YY, Jordan EJ, Kelly CM, Lowery MA, Morris LGT, Omuro AM, Raj N, Razavi P, Shoushtari AN, Shukla N, Soumerai TE, Varghese AM, Yaeger R, Coleman J, Bochner B, Riely GJ, Saltz LB, Scher HI, Sabbatini PJ, Robson ME, Klimstra DS, Taylor BS, Baselga J, Schultz N, Hyman DM, Arcila ME, Solit DB, Ladanyi M, Berger MF. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017 Jun;23(6):703-713. doi: 10.1038/nm.4333. Epub 2017 May 8. Erratum in: Nat Med. 2017 Aug 4;23 (8):1004.</citation>
    <PMID>28481359</PMID>
  </results_reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>January 8, 2019</study_first_submitted>
  <study_first_submitted_qc>January 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2019</study_first_posted>
  <last_update_submitted>October 17, 2019</last_update_submitted>
  <last_update_submitted_qc>October 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Durvalumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

